Press Releases

Press Releases

Date	Title	View
November 9, 2022	AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 2, 2022	AN2 Therapeutics to Present at Upcoming Investor Conferences
October 19, 2022	AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 6, 2022	AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
September 29, 2022	NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
August 29, 2022	AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 11, 2022	AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
June 29, 2022	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
May 10, 2022	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

Investors